Bio Path Holdings Inc (BPTH)

[wordlender]

Got a little mention in this research note here:

http://www.abnewswire.com/pressreleases/chronic-myeloid-leukemia-cml-treatment-market-is-expected-to-hit-us20720-million-by-2023-credence-research_80654.html

We are near the end of their list of "key players":

Market Competition Assessment:
The chronic myeloid leukaemia (CML) market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., Pfizer, Inc., Hospira, Inc., Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Stragen Pharma SA, Otsuka Pharmaceutical Co., Ltd. and Others.


Investors are paying attention to BPTH. Strong results can easily translate into a strong price with BPTH on so many watchlists.